---
title: "ESC 2025: Baxdrostat shows promise in lowering blood pressure in uncontrolled and resistant hypertension"
date: "2025-08-31T15:15:26.000Z"
publishedDate: "31 août 2025"
summary: "Results from the ​BaxHTN phase III trial showed ​baxdrostat (AstraZeneca)—a highly selective aldosterone synthase inhibitor (ASI)—demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with uncontrolled and resistant hypertension who received baxdrostat [&#8230;] The post ESC 2025: Baxdrostat shows promise in lowering blood pressure in uncontrolled and resistant hypertension appeared first on Cardiovascular News ."
importance: ""
sourceUrl: "https://cardiovascularnews.com/esc-2025-baxdrostat-shows-promise-in-lowering-blood-pressure-in-uncontrolled-and-resistant-hypertension/"
tags: ["France", "Actualité", "Cardiovascular News — Latest"]
permalink: "/papers/2025-08-31-esc-2025-baxdrostat-shows-promise-in-lowering-blood-pressure-in-uncontrolled-and-resistant-hypertension"
imageUrl: "https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/blood-pressure.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/esc-2025-baxdrostat-shows-promise-in-lowering-blood-pressure-in-uncontrolled-and-resistant-hypertension/"
---

![ESC 2025: Baxdrostat shows promise in lowering blood pressure in uncontrolled and resistant hypertension](https://cardiovascularnews.com/wp-content/uploads/sites/14/2024/11/blood-pressure.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://cardiovascularnews.com/esc-2025-baxdrostat-shows-promise-in-lowering-blood-pressure-in-uncontrolled-and-resistant-hypertension/*

## L’essentiel

Results from the ​BaxHTN phase III trial showed ​baxdrostat (AstraZeneca)—a highly selective aldosterone synthase inhibitor (ASI)—demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with uncontrolled and resistant hypertension who received baxdrostat [&#8230;] The post ESC 2025: Baxdrostat shows promise in lowering blood pressure in uncontrolled and resistant hypertension appeared first on Cardiovascular News .

## Lien source

https://cardiovascularnews.com/esc-2025-baxdrostat-shows-promise-in-lowering-blood-pressure-in-uncontrolled-and-resistant-hypertension/
